Denver, Colorado - bioAffinity Technologies (NASDAQ:BIAF) released a new clinical case study demonstrating how its noninvasive diagnostic test, CyPath Lung, can help physicians make more confident decisions while sparing patients from unnecessary invasive procedures.
The case involved a 71-year-old former smoker with a history of lung disease and multiple pulmonary nodules detected through low-dose CT scans. One of the nodules measured 7 millimeters, large enough to raise concern for malignancy and often a trigger for more aggressive diagnostic steps such as bronchoscopy or biopsy.
Instead of proceeding immediately to an invasive procedure, physicians incorporated CyPath Lung into the diagnostic process. The test returned an “unlikely malignancy” result, indicating a low probability of cancer. Based on this additional data point, the patient’s pulmonologist opted for a more conservative approach: monitoring the nodules with a follow-up scan rather than moving directly to biopsy.
That decision proved well-founded. A subsequent scan showed that the previously concerning nodules had resolved, suggesting benign inflammation rather than cancer. The remaining nodule was unchanged, further supporting the decision to avoid unnecessary intervention.
The case highlights a persistent clinical challenge, managing small lung nodules in high-risk patients, where uncertainty often leads to invasive and costly procedures. By improving diagnostic clarity, CyPath Lung helps reduce that uncertainty, giving both physicians and patients greater confidence in choosing less aggressive management strategies when appropriate.
CyPath Lung is designed to aid in the early detection of lung cancer using a noninvasive sputum sample. The test combines flow cytometry with artificial intelligence to identify abnormal cell populations associated with malignancy. In clinical studies, it demonstrated 92% sensitivity, 87% specificity, and 88% overall accuracy in detecting lung cancer in high-risk patients with nodules smaller than 20 millimeters.
Beyond its clinical performance, the broader impact is significant. Avoiding unnecessary biopsies can reduce healthcare costs, minimize procedural risks, and ease patient anxiety, particularly for older individuals or those with preexisting lung conditions.
As this case illustrates, integrating noninvasive diagnostics like CyPath Lung into standard care pathways could improve patient outcomes while making lung cancer evaluation more efficient and less invasive.